Search
Hereditary Angioedema (HAE) Clinical Trials
A listing of 5 Hereditary Angioedema (HAE) clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 5 of 5
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Hereditary Angioedema (HAE)
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 5 active clinical trials seeking participants for Hereditary Angioedema (HAE) research studies. The states with the highest number of trials for Hereditary Angioedema (HAE) participants are California, Ohio, Texas and Pennsylvania.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Trial
Vaccine (18+) Clinical Study
Recruiting
We are seeking healthy individuals aged 18 and above who are interested in participating in a vaccine clinical trial.
Conditions:
Vaccine (18+)
Healthy
Healthy Individuals
Healthy Volunteers
Healthy Subjects
A Phase 2 in Adult Subjects With Hereditary Angioedema
Recruiting
A Phase 2 in Adult Subjects with Hereditary Angioedema
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/03/2025
Locations: Raffi Tachdjian, MD Inc, Santa Monica, California +18 locations
Conditions: Hereditary Angioedema (HAE)
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/28/2025
Locations: Study Site, Little Rock, Arkansas +51 locations
Conditions: Hereditary Angioedema (HAE)
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/28/2025
Locations: Study Site, Santa Monica, California +16 locations
Conditions: Hereditary Angioedema (HAE)
A Study of Navenibart in Participants With Hereditary Angioedema
Recruiting
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/23/2025
Locations: Site 9, Birmingham, Alabama +13 locations
Conditions: Hereditary Angioedema (HAE)
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
Recruiting
To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/23/2025
Locations: Institute For Asthma & Allergy, Wheaton, Maryland
Conditions: Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency
1 - 5 of 5